ADARx Pharmaceuticals, Inc. (NasdaqGS: ADRX)
Salud · Biotecnología · US
14,91 $
+12,11 % hoy · -22,9 % 1 año
ADARx Pharmaceuticals, Inc. (NasdaqGS: ADRX) opera en la industria de biotecnología dentro del sector salud. Su valor en bolsa es de 1,67 mil M $ y tiene 100 empleados.
En los últimos doce meses la acción ha bajado un 22,9 % y ha cotizado entre 13,23 y 23,21.
Tweenvest puntúa a ADARx Pharmaceuticals, Inc. en cuatro factores: calidad 64/100, valor 76/100. Su punto más fuerte es valor.
Evolución de la cotización de ADRX
Cifras clave
- Capitalización
- 1,67 mil M $
- Ingresos (últ. 12 m)
- 6,13 M $
- PER
- -22,86
- BPA
- -7,74
- Rent. por dividendo
- —
- Beta (5 años)
- —
- Máximo 52 semanas
- 23,21 $
- Mínimo 52 semanas
- 13,23 $
- Volumen medio (3 m)
- —
- Acciones en circulación
- 112,06 M
- Empleados
- 100
- Próximos resultados
- —
Sobre ADARx Pharmaceuticals, Inc.
ADARx Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on developing siRNA therapeutics to treat a broad spectrum of diseases. The company offers hepatic-targeted programs, including Agazisiran, a complement factor B (CFB) program that represents a pipeline-in-a-product opportunity, where a single therapeutic candidate has the potential to address multiple indications; Onvuzosiran, a clinical program for the prevention of HAE attacks; and ADX-626, a Factor XI (FXI) program for secondary stroke prevention with additional clinical potential for stroke prevention in atrial fibrillation. It also offers extrahepatic-targeted programs, such as ADX-077, an adipose-targeted obesity program designed to reduce body weight and fat while preserving lean mass; and ADX-199, a neuron-targeted program designed to selectively silence and degrade amyloid-ß precursor protein (APP) mRNA in neurons, which is genetically linked to Alzheimer’s disease. The company was incorporated in 2019 and is based in San Diego, California.
- ISIN
- US00654F1057
- Fundada en
- 2019
- Cotiza desde
- 25 sept 2026
- Bolsa
- Nasdaq Global Select
- Divisa
- USD
Otras empresas de biotecnología
| Empresa | Capitalización | Precio | Día |
|---|---|---|---|
| Agios Pharmaceuticals, Inc.NasdaqGS: AGIO | 1,78 mil M $ | 29,68 $ | -0,70 % |
| Recursion Pharmaceuticals, Inc.NasdaqGS: RXRX | 1,76 mil M $ | 2,83 $ | +3,86 % |
| Stoke Therapeutics, Inc.NasdaqGS: STOK | 1,75 mil M $ | 26,68 $ | +1,83 % |
| Nurix Therapeutics, Inc.NasdaqGM: NRIX | 1,69 mil M $ | 15,48 $ | -0,77 % |
| Precigen, Inc.NasdaqGS: PGEN | 1,63 mil M $ | 4,54 $ | -2,58 % |
| Chengdu Olymvax Biopharmaceuticals Inc.SHSE: 688319 | 1,62 mil M $ | 26,68 CN¥ | -3,54 % |
| ABL Bio Inc.KOSDAQ: A298380 | 1,59 mil M $ | 37.850,00 ₩ | -1,43 % |
| Hugel, Inc.KOSDAQ: A145020 | 1,58 mil M $ | 192.300,00 ₩ | -2,09 % |